{"id":4576,"date":"2019-03-29T10:00:42","date_gmt":"2019-03-29T04:30:42","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4576"},"modified":"2024-06-12T15:56:04","modified_gmt":"2024-06-12T10:26:04","slug":"multiple-myeloma-day","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day","title":{"rendered":"Multiple Myeloma Day"},"content":{"rendered":"\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image\"><img decoding=\"async\" width=\"2312\" height=\"2312\" data-id=\"4577\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/17064957\/multiple-myeloma-day.png\" alt=\"multiple myeloma day\" class=\"wp-image-4577\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/17064957\/multiple-myeloma-day.png 2312w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/17064957\/multiple-myeloma-day-1536x1536.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/17064957\/multiple-myeloma-day-2048x2048.png 2048w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/17064957\/multiple-myeloma-day-100x100.png 100w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/17064957\/multiple-myeloma-day-20x20.png 20w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/17064957\/multiple-myeloma-day-250x250.png 250w\" sizes=\"(max-width: 2312px) 100vw, 2312px\" \/><figcaption class=\"wp-element-caption\"><strong>Multiple Myeloma Day<\/strong><\/figcaption><\/figure>\n<\/figure>\n\n\n\n<p class=\"has-background\" style=\"background-color:#ebbac0\"><strong>Multiple\u00a0Myeloma<\/strong> is <g class=\"gr_ gr_9 gr-alert gr_gramm gr_inline_cards gr_run_anim Grammar only-ins replaceWithoutSep\" id=\"9\" data-gr-id=\"9\">relatively<\/g> a rare disease. It accounts for approximately 1% of all <strong>cancers <\/strong>and 10% of all blood and <strong>bone marrow cancers<\/strong>.\u00a0For more information on\u00a0\u00a0<strong>Multiple\u00a0Myeloma<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Multiple\u00a0Myeloma is relatively a rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers.\u00a0For more information on\u00a0\u00a0Multiple\u00a0Myeloma.<\/p>\n","protected":false},"author":1,"featured_media":4601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[410,2833,16669,16671,3010,2264],"industry":[17225],"therapeutic_areas":[17233,17228,17234],"class_list":["post-4576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-multiple-myeloma","tag-multiple-myeloma-drugs-market","tag-multiple-myeloma-market","tag-multiple-myeloma-pipeline","tag-rbc","tag-red-blood-cells","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Multiple Myeloma Day - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Multiple Myeloma is a relatively rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Multiple Myeloma Day - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Multiple Myeloma is a relatively rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-29T04:30:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-12T10:26:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021328\/slide1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2312\" \/>\n\t<meta property=\"og:image:height\" content=\"1156\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Multiple Myeloma Day - DelveInsight Business Research","description":"Multiple Myeloma is a relatively rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day","og_locale":"en_US","og_type":"article","og_title":"Multiple Myeloma Day - DelveInsight Business Research","og_description":"Multiple Myeloma is a relatively rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers...","og_url":"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-03-29T04:30:42+00:00","article_modified_time":"2024-06-12T10:26:04+00:00","og_image":[{"width":2312,"height":1156,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021328\/slide1.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day","url":"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day","name":"Multiple Myeloma Day - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021328\/slide1.png","datePublished":"2019-03-29T04:30:42+00:00","dateModified":"2024-06-12T10:26:04+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Multiple Myeloma is a relatively rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/multiple-myeloma-day#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021328\/slide1.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021328\/slide1.png","width":2312,"height":1156,"caption":"Multiple myeloma market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/09021328\/slide1-300x150.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Multiple MYELOMA drugs Market.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">RBC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">red blood cells<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Multiple MYELOMA drugs Market.<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Pipeline<\/span>","<span class=\"advgb-post-tax-term\">RBC<\/span>","<span class=\"advgb-post-tax-term\">red blood cells<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Mar 29, 2019","modified":"Updated on Jun 12, 2024"},"absolute_dates_time":{"created":"Posted on Mar 29, 2019 10:00 am","modified":"Updated on Jun 12, 2024 3:56 pm"},"featured_img_caption":"Multiple myeloma market","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4576"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4576\/revisions"}],"predecessor-version":[{"id":28277,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4576\/revisions\/28277"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4601"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4576"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4576"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}